Ocular Therapeutix to Reveal Phase 3 SOL-1 Efficacy Data for AXPAXLI in June Summit
OCUL•Ocular Therapeutix, Inc. will showcase Phase 3 SOL-1 trial efficacy outcomes and safety profile data for AXPAXLI™ (OTX-TKI) in neovascular AMD during the Clinical Trials at the Summit 2026 in Las Vegas on June 12–13, 2026. The company will also present a HELIOS program update on AXPAXLI™ in nonproliferative diabetic retinopathy and discuss its ELUTYX™ hydrogel pipeline in expert panels led by its executive chairman.
1. Conference Participation
Ocular Therapeutix will participate in Clinical Trials at the Summit 2026 in Las Vegas on June 12–13, 2026, showcasing its retinal disease pipeline through multiple presentations, fireside chats and panels featuring senior leadership and global key opinion leaders.
2. SOL-1 Phase 3 Trial Presentations
The company will present efficacy outcomes and safety and tolerability data from its SOL-1 Phase 3 superiority trial of AXPAXLI™ (OTX-TKI) for neovascular age-related macular degeneration during two sessions on June 13, detailing vision improvement endpoints and adverse event profiles.
3. HELIOS Program Update
A HELIOS program update on AXPAXLI™ in nonproliferative diabetic retinopathy will be delivered on June 13, providing interim results on retinal thickness reduction and visual acuity changes from ongoing Phase 3 studies.
4. Innovation Panels and Pipeline Overview
Executive Chairman Pravin U. Dugel will join panels discussing the ELUTYX™ bioresorbable hydrogel technology, pipeline candidates including OTX-TIC and commercial product DEXTENZA®, and strategies for accelerating approval of novel ophthalmic therapies.
